Bay Area's Sangamo Surges As Gene Editing Tech Make Cells Repel HIV

Published: Mar 06, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Sangamo BioSciences' (SGMO) first clinical study, a phase 1 trial conducted on six HIV-positive patients over 12 weeks, demonstrates that the T-cell genome can be safely engineered to mimic a naturally occurring mutation that provides resistance to HIV infection. This could potentially be a way to control HIV infection without the use of drugs. In the study, T-cells from the subjects were isolated and edited with ZFNs to make them resistant to the HIV virus by knocking out the CCR5 gene that encodes a coreceptor required for infection.

Help employers find you! Check out all the jobs and post your resume.

Back to news